Companies › Monte Rosa Therapeutics
2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Other, Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MRT-2359 GSPT1 molecular glue degrader | GSPT1 | Phase 2 | Castration-Resistant Prostate Cancer (CRPC); NSCLC | Dec 2026 |
| MRT-8102 | – | Phase 1 | Healthy Volunteers | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07119125 | MRT-8102 | Phase 1 | Healthy Volunteers | Other | Jul 2026 |
| NCT05546268 | MRT-2359 | Phase 1 | NSCLC | Oncology | Dec 2026 |
| NCT07745361 | MRT-2359 | Phase 2 | Castration-Resistant Prostate Cancer (CRPC) | Oncology | Oct 2027 |
Cash and short-term investments of $578m on 2026-09-30; operating cash outflow about $164m a year; runway about 42 months at that burn, to Apr 2030; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
–
Haihe Biopharma J-Pharma Ranok Therapeutics (Hangzhou) Kymera Therapeutics C4 Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.